Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Stock Forecast

Stock Price Forecast

The 5 analysts that cover Theravance Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $27.8, which forecasts a 52.92% increase in the stock price over the next year. The lowest target is $20 and the highest is $40.

Price Target: $27.8 (+52.92%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$20	$27.8	$27	$40
Change	+10.01%	+52.92%	+48.51%	+120.02%

Analyst Ratings

The average analyst rating for Theravance Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	3	3	4	4	4	4
Buy	0	0	0	0	0	1
Hold	2	2	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	4	4	4	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Trevor Allred Oppenheimer	Oppenheimer	Buy Initiates $27	Buy	Initiates	$27	+48.51%	Dec 3, 2025
Julian Harrison BTIG	BTIG	Strong Buy Maintains $25 → $40	Strong Buy	Maintains	$25 → $40	+120.02%	Nov 26, 2025
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $15 → $20	Strong Buy	Maintains	$15 → $20	+10.01%	Nov 11, 2025
Mayank Mamtani B. Riley Securities	B. Riley Securities	Strong Buy Initiates $28	Strong Buy	Initiates	$28	+54.02%	Sep 12, 2025
Julian Harrison BTIG	BTIG	Strong Buy Maintains $24 → $25	Strong Buy	Maintains	$24 → $25	+37.51%	Jun 27, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

109.95M

Increased by 70.78%

from 64.38M

Revenue Next Year

88.60M

Decreased by -19.42%

from 109.95M

EPS This Year

1.92

from -1.15

EPS Next Year

0.96

Decreased by -49.69%

from 1.92

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	71.86M	55.31M	51.35M	57.42M	64.38M	109.95M	88.60M
Revenue Growth	-2.12%	-23.03%	-7.17%	11.84%	12.12%	70.78%	-19.42%
EPS	-4.46	-2.87	11.85	-1.00	-1.15	1.92	0.96
EPS Growth	-	-	-	-	-	-	-49.69%
Forward PE	-	-	-	-	-	9.48	18.84
No. Analysts	-	-	-	-	-	8	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	114.0M	100.6M
Avg	110.0M	88.6M
Low	105.1M	80.4M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	77.1%	-8.5%
Avg	70.8%	-19.4%
Low	63.2%	-26.9%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	2.36	1.37
Avg	1.92	0.96
Low	1.37	0.19

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-28.8%
Avg	-	-49.7%
Low	-	-90.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.